BRAF and melanoma: However, more prolonged interruption of pathway inhibition may provide greater benefits and is being investigated in a clinical trial randomizing patients with advanced BRAF mutant melanoma to continuous or intermittent exposure to dabrafenib and trametinib (NCT02196181).